Cargando…

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System

IMPORTANCE: Using real-world data, the US Department of Veterans Affairs (VA) initiated a surveillance evaluation of edaravone after its approval for amyotrophic lateral sclerosis (ALS) in 2017. The use and safety of edaravone for patients with ALS in the VA health care system remain to be assessed....

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Michelle, Tortorice, Kathryn, Zacher, Jennifer, Dong, Diane, Hur, Kwan, Zhang, Rongping, Good, Chester B., Glassman, Peter A., Cunningham, Francesca E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536587/ https://www.ncbi.nlm.nih.gov/pubmed/33017028 http://dx.doi.org/10.1001/jamanetworkopen.2020.14645

Ejemplares similares

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Outcomes of Veterans Treated in Veterans Affairs Hospitals vs Non–Veterans Affairs Hospitals
por: Yoon, Jean, et al.
Publicado: (2023)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System
por: Radomski, Thomas R., et al.
Publicado: (2016)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis
por: Fabes, Jeremy, et al.
Publicado: (2017)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
por: Soni, Amy, et al.
Publicado: (2015)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

Association Between Spending and Survival of Chronic Heart Failure Across Veterans Affairs Medical Centers
por: Groeneveld, Peter W., et al.
Publicado: (2019)

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis
por: Johnson, Janel O., et al.
Publicado: (2021)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Houzen, Hideki, et al.
Publicado: (2021)

Association of Veterans Affairs Primary Care Mental Health Integration With Care Access Among Men and Women Veterans
por: Leung, Lucinda B., et al.
Publicado: (2020)

Association of Expanded Health Care Networks With Utilization Among Veterans Affairs Enrollees
por: Rose, Liam, et al.
Publicado: (2021)

Mortality After Postcolonoscopy Colorectal Cancer in the Veterans Affairs Health Care System
por: Kahi, Charles J., et al.
Publicado: (2023)

Use of General Primary Care, Specialized Primary Care, and Other Veterans Affairs Services Among High-Risk Veterans
por: Chang, Evelyn T., et al.
Publicado: (2020)

Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target
por: Kankel, Mark W., et al.
Publicado: (2020)

Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes
por: Daneshvar, Daniel H., et al.
Publicado: (2021)

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014)

Assessment of the Medicare Advantage Risk Adjustment Model for Measuring Veterans Affairs Hospital Performance
por: Wagner, Todd H., et al.
Publicado: (2018)

Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System
por: Yamoah, Kosj, et al.
Publicado: (2022)

Association of Use of Electronic Appointment Reminders With Waiting Times in the Veterans Affairs Health System
por: Li, Lianjun, et al.
Publicado: (2022)

Analysis of an Antibiotic Stewardship Program for Asymptomatic Bacteriuria in the Veterans Affairs Health Care System
por: Grigoryan, Larissa, et al.
Publicado: (2022)

A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk
por: Re, Diane B., et al.
Publicado: (2022)

TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis
por: Kurashige, Takashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j3fms57aeqga53jq61ahmll5sa